Compare Bath & Body Works Inc (BBWI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Mesoblast Limited — how do they compare? Bath & Body Works Inc trades at $19.4 (market cap $4.04B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Bath & Body Works Inc is the larger of the two by market cap, and Bath & Body Works Inc pays a 3.99% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BBWI | MESO | |
|---|---|---|
Market Cap | $4.04B | $2.12B |
Sector | Consumer Cyclical | Technology |
52-Week High | $33.11 | $20.96 |
52-Week Low | $14.85 | $10.96 |
Enterprise Value | $7.93B | $2.13B |
Dividend Yield | 3.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $20.42, up 0.44% today, with a bearish technical signal but attractive valuation metrics including a P/E of 5.8 and P/S of 0.58. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. The company maintains solid profitability with a 10.03% net income margin and positive cash flow trends projected for 2026. Strategic initiatives include a new Ulta Beauty partnership and international expansion to drive growth amid declining revenue trends.
Outlook: BBWI presents a value opportunity with deep valuation discounts and operational strengths, though persistent revenue declines and high debt pose risks. Analyst consensus is cautiously optimistic with a $22 price target, suggesting modest upside potential if turnaround efforts gain traction against competitive and macroeconomic headwinds.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
